Last reviewed · How we verify
Etoricoxib (Arcoxia)
Etoricoxib (Arcoxia) is a Selective COX-2 inhibitor (coxib) Small molecule drug developed by Radboud University Medical Center. It is currently FDA-approved for Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis. Also known as: Etoricoxib, Arcoxia, Arcoxia.
Etoricoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing the production of prostaglandins that mediate inflammation and pain.
Etoricoxib, also known as Arcoxia, is a small molecule that inhibits the cyclooxygenase-2 enzyme, specifically targeting prostaglandin G/H synthase 2. It has been studied for various conditions, including postoperative pain, rheumatoid arthritis, ankylosing spondylitis, and pain, among others.
At a glance
| Generic name | Etoricoxib (Arcoxia) |
|---|---|
| Also known as | Etoricoxib, Arcoxia, Arcoxia |
| Sponsor | Radboud University Medical Center |
| Drug class | Selective COX-2 inhibitor (coxib) |
| Target | COX-2 (Cyclooxygenase-2) |
| Modality | Small molecule |
| Therapeutic area | Rheumatology / Pain Management |
| Phase | FDA-approved |
Mechanism of action
As a selective COX-2 inhibitor, etoricoxib blocks the COX-2 enzyme preferentially over COX-1, thereby decreasing prostaglandin synthesis in inflamed tissues. This results in anti-inflammatory and analgesic effects with a potentially improved gastrointestinal safety profile compared to non-selective NSAIDs, though cardiovascular risks remain a consideration.
Approved indications
- Rheumatoid arthritis
- Osteoarthritis
- Ankylosing spondylitis
- Acute pain
- Chronic pain conditions
Common side effects
- Hypertension
- Edema
- Dyspepsia
- Headache
- Cardiovascular events (myocardial infarction, stroke)
Key clinical trials
- Comparative Bioavailability Study Between Etoricoxib / Betamethasone Administered Individually or in Combination (PHASE1)
- Bioequivalence Study of Test and Reference 120 mg Etoricoxib Film-coated Tablets in Healthy Volunteers (PHASE1)
- Survey of Osteoarthritis Real World Therapies (MK-0663-140)
- An Investigational Drug Study in the Treatment of Primary Dysmenorrhea (0663-064) (PHASE3)
- A Study to Assess Etoricoxib Versus Diclofenac in Chinese Patients With Osteoarthritis of the Knee or Hip (0663-080)(COMPLETED) (PHASE4)
- Investigational Drug Versus an Approved Drug in Patients With Osteoarthritis (0663-061)(COMPLETED) (PHASE3)
- Quality of Life With Arcoxia in Women With Dysmenorrhea (0663-094) (PHASE4)
- A Study to Assess the Safety and Efficacy of an Investigational Drug in Patients With Osteoarthritis (0663-071)(COMPLETED) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Etoricoxib (Arcoxia) CI brief — competitive landscape report
- Etoricoxib (Arcoxia) updates RSS · CI watch RSS
- Radboud University Medical Center portfolio CI
Frequently asked questions about Etoricoxib (Arcoxia)
What is Etoricoxib (Arcoxia)?
How does Etoricoxib (Arcoxia) work?
What is Etoricoxib (Arcoxia) used for?
Who makes Etoricoxib (Arcoxia)?
Is Etoricoxib (Arcoxia) also known as anything else?
What drug class is Etoricoxib (Arcoxia) in?
What development phase is Etoricoxib (Arcoxia) in?
What are the side effects of Etoricoxib (Arcoxia)?
What does Etoricoxib (Arcoxia) target?
Related
- Drug class: All Selective COX-2 inhibitor (coxib) drugs
- Target: All drugs targeting COX-2 (Cyclooxygenase-2)
- Manufacturer: Radboud University Medical Center — full pipeline
- Therapeutic area: All drugs in Rheumatology / Pain Management
- Indication: Drugs for Rheumatoid arthritis
- Indication: Drugs for Osteoarthritis
- Indication: Drugs for Ankylosing spondylitis
- Also known as: Etoricoxib, Arcoxia, Arcoxia
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing